Omadacycline is a novel aminomethylcycline tetracycline used for CAP and ABSSSI. Its key pharmacological advantage over older tetracyclines relates to evading the two main resistance mechanisms because omadacycline:

• A Evades TET-M and TET-O ribosomal protection proteins and TET-efflux pumps (TetK, TetB) due to its bulky C9 aminomethyl substituent ✓
• B Is not a substrate for the 30S ribosomal protection pathway as it binds a completely different site on 16S rRNA
• C Is actively secreted by enterocytes making it a preferred oral therapy for intraluminal pathogens
• D Inhibits both 30S protein synthesis and DNA gyrase, creating dual bactericidal action that overcomes single-mechanism resistance

Explanation

Omadacycline is a novel aminomethylcycline (3rd generation tetracycline) with a bulky aminomethyl side chain at C9. This structural modification creates steric interactions that prevent the tet ribosomal protection proteins (TET-M, TET-O, TET-S) from displacing the drug off the ribosome, and also make it a poor substrate for tetracycline-specific efflux pumps (TetK, TetB). Unlike tigecycline, omadacycline has good oral bioavailability (58%) enabling both IV-to-oral switch therapy. It retains activity against many tetracycline-resistant strains. It does not inhibit DNA gyrase.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.